This is a particular need, since a recent study found that IDO-1 expression was paradoxically upregulated in human cancers from 1-D-MT, a compound currently used in a phase 2 clinical study in patients with metastatic breast cancer [56]. The gene discussed is IDO1; the disease is cancer.